Entyvio exhibits favorable real-world safety profile in biologic-naive IBD patients

SAN ANTONIO — Entyvio was associated with significantly fewer serious adverse events and serious infections compared with anti-TNF therapy in biologic-naive patients with inflammatory bowel disease, according to data from the EVOLVE trial presented at the American College of Gastroenterology Annual Meeting.Andres Yarur, MD, assistant professor of medicine at the Medical College of Wisconsin, said the findings offer a real-world perspective on how Entyvio (vedolizumab, Takeda) compares to anti-TNF therapy in practice.“The aim of the EVOLVE trial was to assess real-life experiencesRead More

Share on facebook
Share on twitter
Share on linkedin